Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cerilliant
AstraZeneca
Citi
Boehringer Ingelheim
Moodys
Dow
Harvard Business School
QuintilesIMS

Generated: July 18, 2018

DrugPatentWatch Database Preview

SAVELLA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Savella patents expire, and when can generic versions of Savella launch?

Savella is a drug marketed by Allergan Sales Llc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-seven patent family members in twenty-six countries.

The generic ingredient in SAVELLA is milnacipran hydrochloride. There are twenty-six drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the milnacipran hydrochloride profile page.
Drug patent expirations by year for SAVELLA
Synonyms for SAVELLA
(+-)-cis-2-Aminomethyl-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R-cis)-Milnacipran Hydrochloride
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-cyclopropanecarboxamide hydrochloride
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
(1R,2S)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride; F 2207; Midalcipran; Toledomin
(1RS,2SR)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1S-cis)-Milnacipran Hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride
(1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
(1S,2R)-Milnacipran Hydrochloride
(Z)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
1-Phenyl-1-(diethylaminocarbonyl)-2-(aminomethyl)cyclopropane hydrochloride
1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride
101152-94-7
105310-47-2
1159813-27-0
152M947
175131-60-9
175131-61-0
2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide hydrochloride
2-(aminomethyl)-N,N-diethyl-1-phenyl-cyclopropane-1-carboxamide hydrochloride
2-(Aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide HCl
2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
371U2ZK31U
4CH-002025
86181-08-0
A800340
AB0097998
AB0108218
AB1004578
AC-1532
AC1L4TFV
AC1OCEN6
ACT02608
AK481450
AKOS015950801
AKOS025311514
AKOS025401404
AN-14832
ANW-43127
AOB6178
API0003393
AS-12868
AT-28508
BC219330
C15H22N2O.HCl
CAS-101152-94-7
CCG-101034
CCG-213316
CCG-231710
CHEBI:31854
CHEMBL1237129
CHEMBL2105732
cis-(-)-Milnacipran Hydrochloride
cis-(+-)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
cis-(+)-Milnacipran Hydrochloride
cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
CPD000449266
CS-2010
CS-4972
CTK8B3761
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (Z)-, monohydrochloride
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, monohydrochloride, (1R,2S)-rel-
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, monohydrochloride, cis-(+-)-
D01107
D10133
Dalcipran
DSSTox_CID_26785
DSSTox_GSID_46785
DSSTox_RID_81903
DTXSID4046785
F 2207
F 2695 hydrochloride
F-2207
F2695
Fetzima (TN)
HY-B0168A
HY-B0168B
Ixel
J-011063
J10386
Joncia
K-0218
KS-00000XLX
KS-1274
L-Milnacipran Hydrochloride
Levomilnacipran HCl
LEVOMILNACIPRAN HYDROCHLORIDE
Levomilnacipran hydrochloride (USAN)
Levomilnacipran hydrochloride [USAN]
LS-58540
LS-58541
M2133
MFCD00901293
MFCD01735755
MFCD18433402
Midalcipran hydrochloride
Milnacipran ((1S-cis) hydrochloride)
Milnacipran (1S-cis) hydrochloride
Milnacipran (hydrochloride)
Milnacipran HCl
Milnacipran hydrochloride
Milnacipran hydrochloride (JAN/USAN)
Milnacipran hydrochloride [USAN]
Milnacipran Hydrochloride 1.0 mg/ml in Methanol (as free base)
Milnacipran hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Milnacipran hydrochloride, >=98% (HPLC), solid
MLS000758229
MLS001424149
MolPort-005-940-369
MolPort-006-666-270
MolPort-019-939-251
NC00284
NCGC00168780-01
NSC-759806
NSC759806
OR063822
OR147048
Pharmakon1600-01504815
QC-10074
RTR-000332
s3140
SAM001247035
Savella (TN)
SC-15864
SCHEMBL1148742
SCHEMBL1156056
SCHEMBL161558
SMR000449266
TN-912
Toledomin
Toledomin (TN)
Tox21_112641
TR-000332
UNII-371U2ZK31U
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-NQQJLSKUSA-N
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-PBCQUBLHSA-N
Z-2 Aminomethyl-1-phenyl-N,N-diethylcyclopropane-carboxamide hydrochloride

US Patents and Regulatory Information for SAVELLA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-003 Jan 14, 2009 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Paragraph IV (Patent) Challenges for SAVELLA
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe ➤ Try a Free Trial

Non-Orange Book US Patents for SAVELLA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,635,675 Method of treating chronic fatigue syndrome ➤ Try a Free Trial
7,915,246 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Try a Free Trial
7,820,643 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Medtronic
Chinese Patent Office
Deloitte
US Department of Justice
Farmers Insurance
Covington
Accenture
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.